Nebraska is currently home to 717 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Omaha, Lincoln, Kearney and Grand Island. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
IC-8 Apthera IOL New Enrollment Post Approval Study
NCT06060041
Recruiting
The purpose of this study is to verify the post-market safety of the IC-8 Apthera IOL after the treatment of posterior capsular opacification (PCO), an expected complication related to IC-8 Apthera IOL implantation.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
01/16/2025
Locations: Vance Thompson Vision - Omaha, Omaha, Nebraska
Conditions: Cataract, Presbyopia, Posterior Capsule Opacification
Register for Updates
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
NCT04829604
Recruiting
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: Research Site, Omaha, Nebraska
Conditions: HER2 Positive Metastatic Breast Cancer
Register for Updates
Trial of 225Ac-DOTATATE (RYZ101) in Subjects with ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
NCT06590857
Recruiting
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2025
Locations: Research Facility, Omaha, Nebraska
Conditions: Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
Register for Updates
Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared with Placebo in Adult Participants with Moderate to Severe Hidradenitis Suppurativa
NCT06411379
Recruiting
This is a study to evaluate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa. Participants will be randomized 2:1 to either sonelokimab or matching placebo up to Week 16.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2025
Locations: Clinical Site, Omaha, Nebraska
Conditions: Hidradenitis Suppurativa
Register for Updates
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
NCT06115135
Recruiting
A phase 2 study of venetoclax in combination with isatuximab and dexamethasone for relapsed/refractory multiple myeloma patients with t(11;14)
Gender:
ALL
Ages:
All
Trial Updated:
01/14/2025
Locations: Nebraska Cancer Specialists, Omaha, Nebraska
Conditions: Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Register for Updates
Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients
NCT04217551
Recruiting
A multicenter, randomized, adaptive allocation clinical trial to determine if increasing durations of induced hypothermia are associated with an increasing rate of good neurological outcomes and to identify the optimal duration of induced hypothermia for neuroprotection in comatose survivors of cardiac arrest.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/13/2025
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Cardiac Arrest, Out-Of-Hospital, Hypothermia, Induced, Hypoxia-Ischemia, Brain
Register for Updates
Motivations, Attitudes, and Perceptions Study
NCT05873413
Recruiting
The goal of this clinical trial is to compare the impact of providing participants with 1. A recently developed protocol for motivating bystanders to intervene to help others who are in sexual risk situations (Motivate-the-Bystander) alone 2. Motivate-the-Bystander with an alcohol component focused on reducing drinking behaviors (Motivate-the-Bystander+Alcohol) 3. A control condition focused on reducing stress The main questions it aims to answer are: * Is Motivate-the-Bystander more effectiv... Read More
Gender:
ALL
Ages:
Between 18 years and 25 years
Trial Updated:
01/10/2025
Locations: University of Nebraska-Lincoln, Lincoln, Nebraska
Conditions: Alcohol Drinking, Sexual Violence, Social Norms
Register for Updates
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, the ERASur Study
NCT05673148
Recruiting
This phase III trial compares total ablative therapy and usual systemic therapy to usual systemic therapy alone in treating patients with colorectal cancer that has spread to up to 4 body sites (limited metastatic). The usual approach for patients who are not participating in a study is treatment with intravenous (IV) (through a vein) and/or oral medications (systemic therapy) to help stop the cancer sites from getting larger and the spread of the cancer to additional body sites. Ablative means... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Nebraska Medicine-Bellevue, Bellevue, Nebraska
Conditions: Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8
Register for Updates
Study of INBRX-109 in Conventional Chondrosarcoma
NCT04950075
Recruiting
Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
01/09/2025
Locations: Nebraska Methodist Hospital, Omaha, Nebraska
Conditions: Conventional Chondrosarcoma
Register for Updates
T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
NCT04457596
Recruiting
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Nebraska Medicine-Bellevue, Bellevue, Nebraska
Conditions: Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
Register for Updates
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
NCT03104491
Recruiting
This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of this research study is to see what doses post-transplant inotuzumab ozogamicin can safely be given to subjects without having too many side effects. The Phase II portion of this study is to see what side effects are seen with medication after transplant. Inotuzumab ozogamicin is a combination of an antibody and chemotherapy which has been shown to have significant activity against relapsed/refractory acute... Read More
Gender:
ALL
Ages:
Between 16 years and 75 years
Trial Updated:
01/09/2025
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Acute Lymphocytic Leukemia
Register for Updates
Measuring Outcomes of LASIK and EVO-ICL in Matched Populations
NCT06700460
Recruiting
Evaluating outcomes after bilateral implantation of ICLs or bilateral LASIK as treatment options for the correction or reduction of myopia with or without astigmatism.
Gender:
ALL
Ages:
Between 21 years and 45 years
Trial Updated:
01/07/2025
Locations: Kugler Vision, Omaha, Nebraska
Conditions: Myopia
Register for Updates